Clinical trials: Patients With Diabetes.
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
Primary Objective: The primary objective of this study was to assess the dose-response relationship of SAR425899 versus placebo in terms of glycemic control as measured by the change in glycosylated hemoglobin (HbA1c).
- Trial name
- NCT02973321
- Testing
- SAR425899, Liraglutide, Metformin
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Evaluation of TTP399 in Patients With Type 1 Diabetes
The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing.
- Trial name
- SimpliciT1 (NCT03335371)
- Testing
- TTP399
- Where
- 15 sites in United States
- Volunteers
- 115 people
- Sponsor
- vTv Therapeutics
Type 1 Diabetes Mellitus
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
This Phase 2 study was intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and efficacy of sotagliflozin following daily oral administration for 29 days in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01742208
- Testing
- Sotagliflozin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
The purpose of this study is to try and achieve similar glycemic control in general non-Intensive Care Unit (non-ICU) patients with Type 2 Diabetes with exenatide alone or in combination with basal insulin as compared to…
- Trial name
- NCT02455076
- Testing
- Exenatide, Glargine, Rapid-acting insulin analogs
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Emory University
Type 1 Diabetes
Context Aware Data Gathering Study
Automated Insulin Delivery (AID) systems have now become an important standard-of-care for people with T1D and have demonstrated a reduction, but not elimination, of hypoglycemia during long-term studies.
- Trial name
- NCT04154904
- Testing
- Exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oregon Health and Science University
Diabetic Macular Edema
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The purpose of the study is to test the hypothesis that oral administration of ruboxistaurin will reduce the occurrence of sustained moderate visual loss (SMVL) in patients with clinically significant macular edema.
- Trial name
- NCT00133952
- Testing
- Ruboxistaurin
- Where
- 41 sites in United States, Canada and 8 more
- Volunteers
- 309 people
- Sponsor
- Chromaderm, Inc.
Heart Failure With Preserved Ejection Fraction
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
The clinical benefits of the dual Sodium-Glucose cotransporter (SGLT) 1 and 2-inhibition have recently been reported in two clinical trials.
- Trial name
- NCT05562063
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Juan Badimon
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes.
- Trial name
- SFRNDM2 (NCT05139914)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston University
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
- Trial name
- NCT04093752
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 67 sites in Australia, China and 2 more
- Volunteers
- 917 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate…
- Trial name
- NCT02154347
- Testing
- KAD-1229, Insulin
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Type 1 Diabetes Mellitus
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of secukinumab on the preservation of pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT02044848
- Testing
- Secukinumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment.
- Trial name
- NCT01512849
- Testing
- TA-7284 Low, TA-7284 High
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Tanabe Pharma Corporation
Proteinuric Kidney Disease, Diabetic Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months).
- Conditions
- Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy
- Trial name
- NCT01129557
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Type 2 Diabetes Mellitus
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
This study will explore the effect of exenatide (given twice a day) versus placebo (given twice a day) treatment on change in mean 24-hour heart rate over a 12 week period of drug exposure in patients with type 2 diabetes.
- Trial name
- NCT00516074
- Testing
- exenatide
- Where
- 6 sites in Canada, Netherlands
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Hypertension
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
To evaluate the impact of escalating doses of IW-1973 on endothelial function [using EndoPAT to measure fingertip small vessel pulse volume], blood pressure (BP), and heart rate.
- Trial name
- NCT02906579
- Testing
- IW-1973
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cyclerion Therapeutics
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of sitagliptin and MK0431A in comparison to a commonly used medication in patients with type 2 diabetes.
- Trial name
- NCT00541450
- Testing
- Comparator: sitagliptin phosphate (sitagliptin), sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010) in comparison to placebo, as an add-on treatment to metformin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GetGoal-M-Asia (NCT01169779)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 35 sites in China, Hong Kong and 2 more
- Volunteers
- 391 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.
- Trial name
- AWARD-11 (NCT03495102)
- Testing
- Dulaglutide
- Where
- 208 sites in United States, Argentina and 14 more
- Volunteers
- 1,842 people
- Sponsor
- Eli Lilly and Company
Ischemic Foot Ulcer
Intensive Insulin Treatment and Ischemic Foot Ulcer
We aim to investigate the relationship between skin microvascular function and the first hospitalization for ischemic foot ulcer in patients with type 1 diabetes former randomized during 7.5 years to intensified conventional…
- Trial name
- NCT01957930
- Testing
- Intensified insulin treatment, Standard treatment
- Where
- 2 sites in Sweden
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic…
- Trial name
- NCT02589639
- Testing
- Empagliflozin
- Where
- 48 sites in Japan
- Volunteers
- 269 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.